Drugs in Dev. Infections and Infectious Diseases
Phase I/ Phase II
Germany 
Lead Product(s) : BNT165e
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : CEPI
Deal Size : $145.0 million
Deal Type : Partnership
BioNTech and CEPI Expand Partnership to Strengthen Africa's mRNA Vaccine Ecosystem
Details : BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines like BNT165 against malaria, mpox and tuberculosis in Africa.
Product Name : BNT165e
Product Type : Vaccine
Upfront Cash : Undisclosed
May 29, 2024
Lead Product(s) : BNT165e
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : CEPI
Deal Size : $145.0 million
Deal Type : Partnership
Lead Product(s) : H5N1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CureVac Starts Combined Phase 1/2 Study in Avian Influenza (H5N1) with GSK Collaboration
Details : H5N1 is a pre-pandemic vaccine candidate currently undergoing evaluation in early-stage clinical trials with patients for treating the H5N1 subtype of influenza A virus.
Product Name : H5N1
Product Type : Vaccine
Upfront Cash : Inapplicable
April 24, 2024
Lead Product(s) : H5N1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COR-101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Hospitalized COVID-19 Patient Treated with the Antibody Drug Candidate COR-101
Details : COR-101 is a fully human IgG monoclonal antibody isolated from recovered COVID-19 patients. COR-101 prevents SARS-CoV-2 from infecting new cells by binding the surface of the virus thereby preventing that the virus attaches to human cells.
Product Name : COR-101
Product Type : Antibody
Upfront Cash : Inapplicable
April 23, 2021
Lead Product(s) : COR-101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DZIF-10c
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Cologne University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
Details : Phase 1/2a clinical trials will evaluate the safety, pharmacokinetics, and antiviral activity of BI 767551 administered by intravenous infusion and by inhalation. The first patients have already been enrolled.
Product Name : BI 767551
Product Type : Antibody
Upfront Cash : Inapplicable
December 18, 2020
Lead Product(s) : DZIF-10c
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Cologne University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : European Investment Bank
Deal Size : $112.3 million
Deal Type : Financing
Details : EIB debt instrument will support BioNTech’s global development of BNT162 for prevention of COVID-19 infection as well as scale-up of manufacturing capacity in Europe as part of the company’s global development and supply strategy.
Product Name : BNT162
Product Type : Vaccine
Upfront Cash : Undisclosed
November 06, 2020
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : European Investment Bank
Deal Size : $112.3 million
Deal Type : Financing
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Fosun Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
China Gives the Go-Ahead for Human Trials of BioNTech's COVID Vaccine Candidate
Details : The potential vaccine is one of the two most advanced candidates that BioNTech is working on with its partner Pfizer Inc and they received “fast track” status this week from the U.S. Food and Drug Administration which is designed to speed up the regu...
Product Name : BNT162
Product Type : Vaccine
Upfront Cash : Inapplicable
July 16, 2020
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Fosun Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First clinical trial of a COVID-19 vaccine candidate in Germany. Pfizer and BioNTech plan to initiate trials for BNT162 in the United States upon regulatory approval, which is expected shortly.
Product Name : BNT162
Product Type : Vaccine
Upfront Cash : Inapplicable
April 29, 2020
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biontech And Pfizer to Commence First Clinical Trial of Covid-19 Vaccine Candidates
Details : BioNTech and Pfizer are jointly developing BNT162. The trial is the first clinical trial of a COVID-19 vaccine candidate to start in Germany, and is part of a global development program.
Product Name : BNT162
Product Type : Vaccine
Upfront Cash : Inapplicable
April 22, 2020
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
